{"url_path":"/sec/rvty/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/31791/0000031791-26-000019-index.html","accession_number":"0000031791-26-000019","cik":"0000031791","ticker":"RVTY","issuer_name":"REVVITY, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/31791/0000031791-26-000019-index.html","primary_entity_key":"0000031791","primary_entity_name":"REVVITY, INC."},"word_count":433,"has_tables":true,"body_markdown":"revv-20260405\nREVVITY, INC00000317912026Q1false1/3111,000,0001,000,000————11300,000,000300,000,000111,629,000112,281,000111,629,000112,281,000http://fasb.org/srt/2026#ChiefExecutiveOfficerMember242/1/2742/1/27xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesrevv:employeesxbrli:purerevv:segmentsiso4217:EURrevv:years00000317912025-12-292026-04-050000031791revv:Commonstock1parvaluepershareMember2025-12-292026-04-050000031791revv:RVTYMember2025-12-292026-04-050000031791exch:XNYS2025-12-292026-04-050000031791revv:A1.875Notesdue2026Member2025-12-292026-04-050000031791revv:RVTY21AMember2025-12-292026-04-0500000317912026-05-080000031791us-gaap:ProductMember2025-12-292026-04-050000031791us-gaap:ProductMember2024-12-302025-03-300000031791us-gaap:ServiceMember2025-12-292026-04-050000031791us-gaap:ServiceMember2024-12-302025-03-3000000317912024-12-302025-03-3000000317912026-04-0500000317912025-12-280000031791us-gaap:CommonStockMember2025-12-280000031791us-gaap:AdditionalPaidInCapitalMember2025-12-280000031791us-gaap:RetainedEarningsMember2025-12-280000031791us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-280000031791revv:NetIncomeMemberus-gaap:CommonStockMember2026-04-050000031791us-gaap:RetainedEarningsMember2025-12-292026-04-050000031791revv:OtherComprehensiveLossMemberus-gaap:CommonStockMember2026-04-050000031791us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-292026-04-050000031791revv:DividendsMemberus-gaap:CommonStockMember2026-04-050000031791revv:ExerciseOfEmployeeStockOptionsAndRelatedIncomeTaxBenefitsMemberus-gaap:CommonStockMember2026-04-050000031791us-gaap:CommonStockMember2025-12-292026-04-050000031791us-gaap:AdditionalPaidInCapitalMember2025-12-292026-04-050000031791revv:IssuanceOfCommonStockForEmployeeStockPurchasePlansMemberus-gaap:CommonStockMember2026-04-050000031791revv:PurchasesOfCommonStockMemberus-gaap:CommonStockMember2026-04-050000031791revv:IssuanceOfCommonStockForLongTermIncentiveProgramMemberus-gaap:CommonStockMember2026-04-050000031791revv:StockCompensationMemberus-gaap:CommonStockMember2026-04-050000031791us-gaap:CommonStockMember2026-04-050000031791us-gaap:AdditionalPaidInCapitalMember2026-04-050000031791us-gaap:RetainedEarningsMember2026-04-050000031791us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-04-050000031791us-gaap:CommonStockMember2024-12-290000031791us-gaap:AdditionalPaidInCapitalMember2024-12-290000031791us-gaap:RetainedEarningsMember2024-12-290000031791us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-2900000317912024-12-290000031791revv:NetIncomeMemberus-gaap:CommonStockMember2025-03-300000031791us-gaap:RetainedEarningsMember2024-12-302025-03-300000031791revv:OtherComprehensiveLossMemberus-gaap:CommonStockMember2025-03-300000031791us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-302025-03-300000031791revv:DividendsMemberus-gaap:CommonStockMember2025-03-300000031791revv:ExerciseOfEmployeeStockOptionsAndRelatedIncomeTaxBenefitsMemberus-gaap:CommonStockMember2025-03-300000031791us-gaap:CommonStockMember2024-12-302025-03-300000031791us-gaap:AdditionalPaidInCapitalMember2024-12-302025-03-300000031791revv:IssuanceOfCommonStockForEmployeeStockPurchasePlansMemberus-gaap:CommonStockMember2025-03-300000031791revv:PurchasesOfCommonStockMemberus-gaap:CommonStockMember2025-03-300000031791revv:IssuanceOfCommonStockForLongTermIncentiveProgramMemberus-gaap:CommonStockMember2025-03-300000031791revv:StockCompensationMemberus-gaap:CommonStockMember2025-03-300000031791us-gaap:CommonStockMember2025-03-300000031791us-gaap:AdditionalPaidInCapitalMember2025-03-300000031791us-gaap:RetainedEarningsMember2025-03-300000031791us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-3000000317912025-03-300000031791srt:AmericasMemberrevv:LifeSciencesMember2025-12-292026-04-050000031791srt:AmericasMemberrevv:DiagnosticsMember2025-12-292026-04-050000031791srt:AmericasMember2025-12-292026-04-050000031791srt:AmericasMemberrevv:LifeSciencesMember2024-12-302025-03-300000031791srt:AmericasMemberrevv:DiagnosticsMember2024-12-302025-03-300000031791srt:AmericasMember2024-12-302025-03-300000031791srt:EuropeMemberrevv:LifeSciencesMember2025-12-292026-04-050000031791srt:EuropeMemberrevv:DiagnosticsMember2025-12-292026-04-050000031791srt:EuropeMember2025-12-292026-04-050000031791srt:EuropeMemberrevv:LifeSciencesMember2024-12-302025-03-300000031791srt:EuropeMemberrevv:DiagnosticsMember2024-12-302025-03-300000031791srt:EuropeMember2024-12-302025-03-300000031791srt:AsiaMemberrevv:LifeSciencesMember2025-12-292026-04-050000031791srt:AsiaMemberrevv:DiagnosticsMember2025-12-292026-04-050000031791srt:AsiaMember2025-12-292026-04-050000031791srt:AsiaMemberrevv:LifeSciencesMember2024-12-302025-03-300000031791srt:AsiaMemberrevv:DiagnosticsMember2024-12-302025-03-300000031791srt:AsiaMember2024-12-302025-03-300000031791revv:LifeSciencesMember2025-12-292026-04-050000031791revv:DiagnosticsMember2025-12-292026-04-050000031791revv:LifeSciencesMember2024-12-302025-03-300000031791revv:DiagnosticsMember2024-12-302025-03-300000031791revv:LifeSciencesSolutionsMemberrevv:LifeSciencesMember2025-12-292026-04-050000031791revv:LifeSciencesSolutionsMemberrevv:DiagnosticsMember2025-12-292026-04-050000031791revv:LifeSciencesSolutionsMember2025-12-292026-04-050000031791revv:LifeSciencesSolutionsMemberrevv:LifeSciencesMember2024-12-302025-03-300000031791revv:LifeSciencesSolutionsMemberrevv:DiagnosticsMember2024-12-302025-03-300000031791revv:LifeSciencesSolutionsMember2024-12-302025-03-300000031791revv:SoftwareMemberrevv:LifeSciencesMember2025-12-292026-04-050000031791revv:SoftwareMemberrevv:DiagnosticsMember2025-12-292026-04-050000031791revv:SoftwareMember2025-12-292026-04-050000031791revv:SoftwareMemberrevv:LifeSciencesMember2024-12-302025-03-300000031791revv:SoftwareMemberrevv:DiagnosticsMember2024-12-302025-03-300000031791revv:SoftwareMember2024-12-302025-03-300000031791revv:ImmunodiagnosticsMemberrevv:LifeSciencesMember2025-12-292026-04-050000031791revv:ImmunodiagnosticsMemberrevv:DiagnosticsMember2025-12-292026-04-050000031791revv:ImmunodiagnosticsMember2025-12-292026-04-050000031791revv:ImmunodiagnosticsMemberrevv:LifeSciencesMember2024-12-302025-03-300000031791revv:ImmunodiagnosticsMemberrevv:DiagnosticsMember2024-12-302025-03-300000031791revv:ImmunodiagnosticsMember2024-12-302025-03-300000031791revv:ReproductiveHealthMemberrevv:LifeSciencesMember2025-12-292026-04-050000031791revv:ReproductiveHealthMemberrevv:DiagnosticsMember2025-12-292026-04-050000031791revv:ReproductiveHealthMember2025-12-292026-04-050000031791revv:ReproductiveHealthMemberrevv:LifeSciencesMember2024-12-302025-03-300000031791revv:ReproductiveHealthMemberrevv:DiagnosticsMember2024-12-302025-03-300000031791revv:ReproductiveHealthMember2024-12-302025-03-300000031791revv:AppliedGenomicsMember2024-12-302025-03-300000031791currency:USDrevv:AdvancedChemistryDevelopmentInc.Member2025-12-292026-04-050000031791currency:USDrevv:AdvancedChemistryDevelopmentInc.Member2026-04-050000031791revv:AdvancedChemistryDevelopmentInc.Member2026-04-050000031791revv:LifeSciencesMemberrevv:AdvancedChemistryDevelopmentInc.Memberrevv:DevelopedTechnologyMember2026-04-050000031791revv:LifeSciencesMemberrevv:AdvancedChemistryDevelopmentInc.Memberus-gaap:TrademarksAndTradeNamesMember2026-04-050000031791revv:LifeSciencesMemberrevv:AdvancedChemistryDevelopmentInc.Memberus-gaap:CustomerRelationshipsMember2026-04-050000031791revv:LifeSciencesMemberrevv:AdvancedChemistryDevelopmentInc.Memberus-gaap:OrderOrProductionBacklogMember2026-04-050000031791revv:LifeSciencesMemberrevv:AdvancedChemistryDevelopmentInc.Member2025-12-292026-04-050000031791revv:CorporateExpensesMember2025-12-292026-04-050000031791revv:CorporateExpensesMember2024-12-302025-03-300000031791revv:LineOfCreditMaturingJanuary72030Member2026-04-050000031791revv:A1900SeniorUnsecuredNotesDue2028Member2026-04-050000031791revv:A1900SeniorUnsecuredNotesDue2028Memberus-gaap:FairValueInputsLevel2Member2026-04-050000031791revv:A3.3PercentTenYearSeniorUnsecuredNotesdueinSept2029Member2026-04-050000031791revv:A3.3PercentTenYearSeniorUnsecuredNotesdueinSept2029Memberus-gaap:FairValueInputsLevel2Member2026-04-050000031791revv:A255PercentSeniorUnsecuredNotesDueIn2031Member2026-04-050000031791revv:A255PercentSeniorUnsecuredNotesDueIn2031Memberus-gaap:FairValueInputsLevel2Member2026-04-050000031791revv:A2250SeniorUnsecuredNotesDueIn2031Member2026-04-050000031791revv:A2250SeniorUnsecuredNotesDueIn2031Memberus-gaap:FairValueInputsLevel2Member2026-04-050000031791revv:A3625PercentSeniorUnsecuredNotesDueIn2051Member2026-04-050000031791revv:A3625PercentSeniorUnsecuredNotesDueIn2051Memberus-gaap:FairValueInputsLevel2Member2026-04-050000031791us-gaap:LongTermDebtMember2026-04-050000031791us-gaap:FairValueInputsLevel2Member2026-04-050000031791revv:A1.875PercentTenYearSeniorUnsecuredNotesMember2026-04-050000031791revv:A1.875PercentTenYearSeniorUnsecuredNotesMemberus-gaap:FairValueInputsLevel2Member2026-04-050000031791revv:LineOfCreditMaturingJanuary72030Member2025-01-072025-01-070000031791revv:LineOfCreditMaturingAugust242026Member2025-01-072025-01-070000031791revv:LineOfCreditMaturingJanuary72030Member2025-01-070000031791us-gaap:LineOfCreditMemberrevv:LineOfCreditMaturingJanuary72030Memberrevv:FederalFundsRateMember2025-12-292026-04-050000031791us-gaap:LineOfCreditMemberrevv:LineOfCreditMaturingJanuary72030Memberus-gaap:SecuredOvernightFinancingRateSofrMember2025-12-292026-04-050000031791revv:LifeSciencesMemberrevv:ReportableSegmentRevenueMember2025-12-292026-04-050000031791revv:DiagnosticsMemberrevv:ReportableSegmentRevenueMember2025-12-292026-04-050000031791revv:ReportableSegmentRevenueMember2025-12-292026-04-050000031791revv:LifeSciencesMemberrevv:ReportableSegmentRevenueMember2024-12-302025-03-300000031791revv:DiagnosticsMemberrevv:ReportableSegmentRevenueMember2024-12-302025-03-300000031791revv:ReportableSegmentRevenueMember2024-12-302025-03-300000031791revv:LifeSciencesMemberrevv:SegmentOperatingIncomeMember2025-12-292026-04-050000031791revv:DiagnosticsMemberrevv:SegmentOperatingIncomeMember2025-12-292026-04-050000031791revv:LifeSciencesMemberrevv:SegmentOperatingIncomeMember2024-12-302025-03-300000031791revv:DiagnosticsMemberrevv:SegmentOperatingIncomeMember2024-12-302025-03-300000031791revv:SegmentOperatingIncomeMember2025-12-292026-04-050000031791revv:SegmentOperatingIncomeMember2024-12-302025-03-300000031791revv:ReconcilingItemToReconcileSegmentOperatingIncomeToIncomeFromContinuingOperationsBeforeIncomeTaxesMember2025-12-292026-04-050000031791revv:ReconcilingItemToReconcileSegmentOperatingIncomeToIncomeFromContinuingOperationsBeforeIncomeTaxesMember2024-12-302025-03-300000031791revv:CorporateReconcilingItemMember2025-12-292026-04-050000031791revv:CorporateReconcilingItemMember2024-12-302025-03-300000031791revv:RepurchaseProgram10232025Member2025-10-232025-10-230000031791revv:RepurchaseProgram10232025Member2025-10-230000031791revv:RepurchaseProgram10232025Member2025-12-292026-04-050000031791revv:RepurchaseProgram10232025Member2026-04-050000031791us-gaap:SubsequentEventMemberrevv:RepurchaseProgram10232025Member2026-04-062026-07-0500000317912025-06-302025-09-2800000317912025-09-292025-12-2800000317912025-03-312025-06-290000031791revv:O2026Q1DividendsMember2026-04-050000031791revv:O2026Q1DividendsMember2025-12-292026-04-050000031791us-gaap:SubsequentEventMemberrevv:O2026Q1DividendsMember2026-05-080000031791us-gaap:SubsequentEventMemberrevv:O2026Q2DividendsMember2026-04-062026-07-050000031791us-gaap:SubsequentEventMemberrevv:O2026Q2DividendsMember2026-08-140000031791revv:LifeSciencesMember2025-12-280000031791revv:DiagnosticsMember2025-12-280000031791revv:LifeSciencesMember2026-04-050000031791revv:DiagnosticsMember2026-04-050000031791us-gaap:PatentsMember2026-04-050000031791us-gaap:PatentsMember2025-12-280000031791revv:TradeNamesAndTrademarksMember2026-04-050000031791revv:TradeNamesAndTrademarksMember2025-12-280000031791us-gaap:LicensingAgreementsMember2026-04-050000031791us-gaap:LicensingAgreementsMember2025-12-280000031791revv:CoreTechnologyMember2026-04-050000031791revv:CoreTechnologyMember2025-12-280000031791us-gaap:CustomerRelationshipsMember2026-04-050000031791us-gaap:CustomerRelationshipsMember2025-12-280000031791revv:EuropeanAndAsianCurrenciesMember2025-12-292026-04-050000031791us-gaap:FairValueHedgingMember2026-04-050000031791us-gaap:FairValueHedgingMember2025-12-280000031791us-gaap:NetInvestmentHedgingMemberrevv:A1.875PercentTenYearSeniorUnsecuredNotesMembercurrency:EUR2025-12-292026-04-050000031791us-gaap:NetInvestmentHedgingMemberrevv:A1.875PercentTenYearSeniorUnsecuredNotesMember2025-12-292026-04-050000031791us-gaap:NetInvestmentHedgingMemberrevv:A1.875PercentTenYearSeniorUnsecuredNotesMember2024-12-302025-03-300000031791us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2026-04-050000031791us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2026-04-050000031791us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2026-04-050000031791us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2026-04-050000031791us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-280000031791us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-280000031791us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-280000031791us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-280000031791revv:AnalyticalFoodAndEnterpriseServicesBusinessesMember2023-03-130000031791revv:SeniorUnsecuredNotesMemberus-gaap:FairValueInputsLevel2Member2026-04-050000031791revv:SeniorUnsecuredNotesMemberus-gaap:FairValueInputsLevel2Member2025-12-280000031791revv:JoelS.GoldbergMember2025-12-292026-04-050000031791revv:JoelS.GoldbergMember2026-04-050000031791revv:PrahladSinghMember2025-12-292026-04-050000031791revv:PrahladSinghMember2026-04-05\n\n[Table of Contents](#i0499c4567bc54f22a925e72b7a1c2abd_7)\n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWashington, D.C. 20549\n\n_______________________________________ \n\nFORM 10-Q\n\n_______________________________________ \n\n(Mark One)\n\n☑QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\nFor the quarterly period ended April 5, 2026\n\nor\n\n☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\nFor the transition period from ____________ to ____________\n\nCommission File Number 001-5075\n\n_______________________________________ \n\nRevvity, Inc.\n\n(Exact name of Registrant as specified in its Charter)\n\n_______________________________________  \n\nMassachusetts 04-2052042\n\n(State or other jurisdiction of\nincorporation or organization) (I.R.S. Employer\nIdentification No.)\n\n77 4th Avenue,Waltham,Massachusetts02451\n\n(Address of principal executive offices)(Zip Code)\n\n(781) 663-6900\n\n(Registrant’s telephone number, including area code)\n\n______________________________________ \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\nTitle of each classTrading Symbol (s)Name of each exchange on which registered\n\nCommon stock, $1 par value per shareRVTYThe New York Stock Exchange\n\n1.875% Notes due 2026RVTY 26The New York Stock Exchange\n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☑    No  ☐\n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☑    No  ☐\n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act. \n\n[Table of Contents](#i0499c4567bc54f22a925e72b7a1c2abd_7)\n\nLarge accelerated filer☑Accelerated filer☐\n\nNon-accelerated filer☐Smaller reporting company☐\n\nEmerging growth company☐\n\nIf an emerging growth company, indicate by check mark whether the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐\n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  ☑\n\nAs of May 8, 2026, there were outstanding 111,559,773 shares of common stock, $1 par value per share.\n\n[Table of Contents](#i0499c4567bc54f22a925e72b7a1c2abd_7)\n\nTABLE OF CONTENTS\n\n \n\n  Page\n\nPART I. FINANCIAL INFORMATION"}